Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.12789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Eline C B Eskes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Enzyme Replacement Therapy, Quality of Life. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Acid sphingomyelinase deficiency (ASMD) is an ultra‐rare lysosomal storage disease with a broad spectrum of manifestations ranging from severe neuropathic forms to attenuated, chronic visceral forms. Manifestations of the chronic visceral subtype are variable and encompass different degrees of hepatosplenomegaly, pulmonary disease and dyslipidemia. The aim of this study was to provide insights into the natural course of adult patients with the chronic visceral subtype. Based on these insights, we proposed tentative criteria for initiation and follow‐up of enzyme replacement therapy (ERT). The data of 23 adult patients were collected in a prospective study. Clinical, genetic and demographic data, plasma measurements, abdominal imaging, pulmonary imaging, pulmonary function tests and quality of life questionnaires were collected. Stability of disease based on several clinical, biochemical and radiological markers (i.e., spleen volume, platelet levels, liver volume, alanine aminotransferase [ALT] levels, diffusion capacity of the lungs for carbon monoxide [DLCO] chitotriosidase activity and lysosphingomyelin [LSM]) was assessed. Cardiovascular risk was estimated based on sex, age, smoking, systolic blood pressure and lipid profile. Quality of life was evaluated with the 36‐Item Short Form Health Survey and the Health Assessment Questionnaire. Median follow‐up was 6.1 years (range 1.3–19.5 years). The most common manifestations were splenomegaly (100%), decreased high‐density lipoprotein cholesterol (HDL‐C) plasma levels (83%), (signs of) steatosis measured with transient elastography (82%), thrombocytopenia (64%), hepatomegaly (52%) and decreased diffusion capacity (45%). The majority of markers remained stable during follow‐up. Twelve patients showed progression of disease: four for spleen volume, two for liver volume, three for DLCO, seven for chitotriosidase activity and three for LSM. One patient showed progression of disease based on four markers, although this patient did not report any problems at the last visit. Cardiovascular risk was estimated and was increased in half of the patients older than 40 years. Patient‐reported quality of life did not differ from the general population, but differences in median 36‐Item Short Form Health Survey (SF‐36) scores of patients with severe pulmonary involvement and those of patients without pulmonary involvement were observed. Tentative criteria for initiation and effect of therapy were proposed. In conclusion, the chronic visceral subtype of ASMD showed a predominantly stable disease course in this cohort. We propose that ERT should be initiated on an individual basis and only in case of progression or symptomatic disease. Collection and analysis of real world data are necessary to refine start, stop and follow‐up criteria in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Gastroenterology Endocrinology Metabolism, Inborn Errors of Metabolism, Amsterdam, The Netherlands.
- Department of Pediatric Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Emma Children's Hospital, Amsterdam, The Netherlands.
- Laboratory Genetic Metabolic Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
- Department of Medical Biochemistry, Leiden Institute of Chemistry, University of Leiden, Leiden, The Netherlands.
- Department of Internal Medicine, Radboud UMC, Nijmegen, Netherlands.
ORCID-Profile: Eline C B Eskes, Laura van Dussen, Marion M M G Brands, Frédéric M Vaz, Johannes M F G Aerts, André B P van Kuilenburg, Barbara Sjouke, Carla E M Hollak
Zitieren
APA
Eskes, E. C. B., van Dussen, L., Brands, M. M. M. G., Vaz, F. M., Aerts, J. M. F. G., van Kuilenburg, A. B. P., Sjouke, B., & Hollak, C. E. M. (2025). Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.12789
Vancouver
Eskes ECB, van Dussen L, Brands MMMG, Vaz FM, Aerts JMFG, van Kuilenburg ABP, et al. Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.12789
BibTeX
@article{Eskes2025,
author = {Eskes, Eline C B and van Dussen, Laura and Brands, Marion M M G and Vaz, Frédéric M and Aerts, Johannes M F G and van Kuilenburg, André B P and Sjouke, Barbara and Hollak, Carla E M},
title = {Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.12789}
}
EUVIMED